Paratek Pharmaceuticals Inc., of Boston, completed enrollment in the pivotal phase III clinical study of intravenous and once-daily oral formulations of omadacycline, a broad-spectrum antibiotic, compared to linezolid to treat acute bacterial skin and skin structure infections.